CA3155177A1 - Process for the production of 5-(4-((2s,5s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1h-1,2,4-triazol-3-amine - Google Patents
Process for the production of 5-(4-((2s,5s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1h-1,2,4-triazol-3-amineInfo
- Publication number
- CA3155177A1 CA3155177A1 CA3155177A CA3155177A CA3155177A1 CA 3155177 A1 CA3155177 A1 CA 3155177A1 CA 3155177 A CA3155177 A CA 3155177A CA 3155177 A CA3155177 A CA 3155177A CA 3155177 A1 CA3155177 A1 CA 3155177A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- compound
- methylmorpholino
- piperidin
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962905494P | 2019-09-25 | 2019-09-25 | |
| PL43126919 | 2019-09-25 | ||
| PLP.431269 | 2019-09-25 | ||
| US62/905,494 | 2019-09-25 | ||
| PCT/IB2020/058984 WO2021059220A1 (en) | 2019-09-25 | 2020-09-25 | Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3155177A1 true CA3155177A1 (en) | 2021-04-01 |
Family
ID=73139065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3155177A Pending CA3155177A1 (en) | 2019-09-25 | 2020-09-25 | Process for the production of 5-(4-((2s,5s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1h-1,2,4-triazol-3-amine |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11746107B2 (https=) |
| EP (1) | EP4041726B8 (https=) |
| JP (1) | JP7697933B2 (https=) |
| KR (1) | KR20220069008A (https=) |
| CN (1) | CN114466845B (https=) |
| AU (1) | AU2020356534B2 (https=) |
| BR (1) | BR112022005420A2 (https=) |
| CA (1) | CA3155177A1 (https=) |
| ES (1) | ES3056105T3 (https=) |
| IL (1) | IL291569B2 (https=) |
| MX (1) | MX2022002881A (https=) |
| PH (1) | PH12022550713A1 (https=) |
| PL (1) | PL4041726T3 (https=) |
| TW (3) | TWI769532B (https=) |
| WO (1) | WO2021059220A1 (https=) |
| ZA (1) | ZA202204542B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022002881A (es) | 2019-09-25 | 2022-06-08 | Oncoarendi Therapeutics Sa | Proceso para la produccion de 5-(4-((2s,5s)-5-(4-clorobencil)-2-me tilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2802530B1 (fr) * | 1999-12-17 | 2002-02-22 | Sanofi Synthelabo | Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant |
| ATE354568T1 (de) * | 2000-08-08 | 2007-03-15 | Ortho Mcneil Pharm Inc | Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden |
| PE20142366A1 (es) * | 2012-05-30 | 2015-01-10 | Hoffmann La Roche | Compuestos triazolo como inhibidores de pde 10 |
| EP3082805B1 (en) * | 2013-12-20 | 2020-02-05 | Institute for Drug Discovery, LLC | Substituted amino triazoles, and methods using same |
| US9440953B2 (en) | 2014-12-19 | 2016-09-13 | OncoArendi Therapeutics Sp. z o.o. | Substituted amino triazoles useful as acidic mammalian chitinase inhibitors |
| GB201513740D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
| PL415078A1 (pl) * | 2015-09-04 | 2017-03-13 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków |
| MX2022000306A (es) | 2019-07-15 | 2022-03-11 | Oncoarendi Therapeutics Sa | Amino triazoles sustituidos utiles como inhibidores de quitinasa. |
| MX2022002881A (es) | 2019-09-25 | 2022-06-08 | Oncoarendi Therapeutics Sa | Proceso para la produccion de 5-(4-((2s,5s)-5-(4-clorobencil)-2-me tilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina. |
-
2020
- 2020-09-25 MX MX2022002881A patent/MX2022002881A/es unknown
- 2020-09-25 TW TW109133211A patent/TWI769532B/zh active
- 2020-09-25 KR KR1020227009777A patent/KR20220069008A/ko active Pending
- 2020-09-25 JP JP2022519042A patent/JP7697933B2/ja active Active
- 2020-09-25 PL PL20803247.4T patent/PL4041726T3/pl unknown
- 2020-09-25 TW TW111121583A patent/TWI849432B/zh active
- 2020-09-25 BR BR112022005420A patent/BR112022005420A2/pt unknown
- 2020-09-25 CA CA3155177A patent/CA3155177A1/en active Pending
- 2020-09-25 TW TW113127475A patent/TWI892762B/zh active
- 2020-09-25 CN CN202080067709.7A patent/CN114466845B/zh active Active
- 2020-09-25 ES ES20803247T patent/ES3056105T3/es active Active
- 2020-09-25 US US17/032,232 patent/US11746107B2/en active Active
- 2020-09-25 PH PH1/2022/550713A patent/PH12022550713A1/en unknown
- 2020-09-25 AU AU2020356534A patent/AU2020356534B2/en active Active
- 2020-09-25 IL IL291569A patent/IL291569B2/en unknown
- 2020-09-25 EP EP20803247.4A patent/EP4041726B8/en active Active
- 2020-09-25 WO PCT/IB2020/058984 patent/WO2021059220A1/en not_active Ceased
-
2022
- 2022-04-22 ZA ZA2022/04542A patent/ZA202204542B/en unknown
-
2023
- 2023-07-17 US US18/222,679 patent/US12319677B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022549863A (ja) | 2022-11-29 |
| PL4041726T3 (pl) | 2026-02-23 |
| ZA202204542B (en) | 2023-01-25 |
| EP4041726B1 (en) | 2025-09-17 |
| EP4041726A1 (en) | 2022-08-17 |
| CN114466845B (zh) | 2024-12-17 |
| IL291569B1 (en) | 2024-12-01 |
| EP4041726C0 (en) | 2025-09-17 |
| TW202448877A (zh) | 2024-12-16 |
| IL291569A (en) | 2022-05-01 |
| PH12022550713A1 (en) | 2024-02-12 |
| IL291569B2 (en) | 2025-04-01 |
| JP7697933B2 (ja) | 2025-06-24 |
| WO2021059220A1 (en) | 2021-04-01 |
| EP4041726B8 (en) | 2025-11-26 |
| US20210147401A1 (en) | 2021-05-20 |
| CN114466845A (zh) | 2022-05-10 |
| TW202126644A (zh) | 2021-07-16 |
| TWI769532B (zh) | 2022-07-01 |
| US20240025889A1 (en) | 2024-01-25 |
| BR112022005420A2 (pt) | 2022-06-21 |
| AU2020356534A1 (en) | 2022-05-19 |
| TWI849432B (zh) | 2024-07-21 |
| ES3056105T3 (en) | 2026-02-18 |
| US11746107B2 (en) | 2023-09-05 |
| US12319677B2 (en) | 2025-06-03 |
| MX2022002881A (es) | 2022-06-08 |
| AU2020356534B2 (en) | 2026-04-09 |
| KR20220069008A (ko) | 2022-05-26 |
| TWI892762B (zh) | 2025-08-01 |
| TW202237594A (zh) | 2022-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10035802B2 (en) | Solid state forms of ibrutinib | |
| CN104470913B (zh) | 用于制造羟基化的环戊基嘧啶化合物的方法 | |
| JP6081450B2 (ja) | アセナピンの結晶塩 | |
| CN108601355A (zh) | 制备激酶抑制剂及其中间体的方法 | |
| US12319677B2 (en) | Process for the production of 5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methyl-morpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine | |
| US20090137821A1 (en) | Method of making dorzolamide hydrochloride | |
| EP3820878A1 (en) | Process for preparing sulfonamide compounds | |
| KR101783679B1 (ko) | ２－（사이클로헥실메틸）－ｎ－｛２－［（２ｓ）－1－메틸피롤리딘－２－일］에틸｝－１，２，３，４－테트라하이드로이소퀴놀린－７－설폰아마이드의 제조 방법 | |
| JP2015042683A (ja) | ビフェニルイミダゾール化合物の調製方法 | |
| WO2014081047A1 (en) | Process for the preparation of (1s,4s,5s)-4-bromo-6-oxabicyclo[3.2.1] octan-7-one | |
| CA2550477C (en) | Process for obtaining tolterodine | |
| HK40080939B (en) | Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine | |
| HK40080939A (en) | Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine | |
| US20090264648A1 (en) | Synthesis of pyrazoles | |
| WO2009053424A1 (en) | Crystalline salt of montelukast | |
| JP2022549863A5 (https=) | ||
| US20120041211A1 (en) | Novel process for preparing carboxy-containing pyrazoleamido compounds 597 | |
| KR101752449B1 (ko) | 솔리페나신 또는 그 염의 결정형 제조방법, 이에 사용되는 신규 중간체 및 그 제조방법 | |
| CA3214107A1 (en) | New process for the synthesis of 5-{5-chloro-2-[(3s)-3- [(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h)- carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds | |
| CN121443612A (zh) | 吡咯并[2,3-d]嘧啶化合物的改进制造方法和中间体及其用途 | |
| WO2026093943A1 (en) | Chemical process for preparing phenylpiperidinyl indole derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240826 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240826 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240826 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240924 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241031 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241114 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241206 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250108 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250108 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250422 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250903 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250903 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260108 |